Horm Metab Res 2019; 51(09): 559-567
DOI: 10.1055/a-0994-0489
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

The Risk For Malignancy of the Thyroid Nodule is Modulated by Gender, Echotexture, and Intranodular Lymphocytic Thyroiditis

Salvatore Arena
1   A.S.P. 8 Siracusa, Section of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Umberto I Hospital, Siracusa, Italy
,
Salvatore Benvenga
2   Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
3   Interdepartmental Program of Molecular & Clinical Endocrinology, and Women’s Endocrine Health, AOU Policlinico G. Martino, Messina, Italy
4   Master Program on Childhood, Adolescent and Women’s Endocrine Health, University of Messina, Messina, Italy
› Author Affiliations
Further Information

Publication History

received 16 February 2019

accepted 06 August 2019

Publication Date:
10 September 2019 (online)

Abstract

Based on the American (Bethesda, 2017) or Italian (SIAPEC 2014) cytological categories of thyroid nodules, the risk of malignancy and management vary. This risk is 5–10% or<3% (benign or TIR2), 6–18% or<10% (AUS/FLUS or TIR3A), 10–40% or 15–30% (FN/SFN or TIR3B), 45–60% or 60–80% (suspicious or TIR4), 94–96% or 95% (malignant or TIR5). In 408 thyroid nodules evaluated cytologically, we computed the malignancy rate in each category considering gender (325 females, 83 males), echotexture (268 isoechoic, 140 hypoechoic), intranodular chronic lymphocytic thyroiditis (ICLT: 113 with and 295 without); histology (263 benign, 145 malignant). It was 0–1.7% for the benign categories, except hypoechoic/ICLT+ve nodules of females (25%); 0–2.3% for the AUS/FLUS category, except isoechoic/ICLT–ve nodules of males (11.1%) and hypoechoic/ICLT–ve nodules of females (22.2%). For the FN/SFN category, rate was the most variable (from 0% in isoechoic/ICLT+ve nodules of males to 100% in hypoechoic/ICLT–ve nodules of males). The 30% threshold for risk was passed in four subgroups, and the 40% threshold in two subgroups (45% in isoechoic/ICLT–ve nodules of males, 80% in hypoechoic/ICLT+ve nodules of females). For the suspicious category, rate was 100% in males, except those with isoechoic/ICLT–ve nodules (75%), and>80% in females with hypoechoic nodules. For the malignant category, rate was always 100%. In conclusion, particular groups of nodules (based on gender, echotexture, and ICLT) within the cytologically benign through the suspiciously malignant category are at risk of malignancy substantially greater (even 100%) than the standard one. Accordingly, the suggested management cannot be standardized.

 
  • References

  • 1 Francis GL, Waguespack SG, Bauer AJ. et al. American Thyroid Association Guidelines Task Force. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 2015; 25: 716-759
  • 2 Haugen BR, Alexander EK, Bible KC. et al. American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1-133
  • 3 Nardi F, Basolo F, Crescenzi A. et al. Italian consensus for the classification and reporting of thyroid cytology. J Endocrinol Invest 2014; 37: 593-599
  • 4 Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid 2009; 19: 1159-1165
  • 5 Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 2017; 27: 1341-1346
  • 6 Nikiforov YE, Seethala RR, Tallini G. et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: A paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2016; 2: 1023-1029
  • 7 Arena S, Benvenga S. Gender-specific correlation of intranodular chronic lymphocytic thyroiditis with thyroid nodule size, echogenicity, and histologically-verified cytological class of malignancy risk. J Clin Transl Endocrinol 2018; 14: 39-45
  • 8 Cooper DS, Doherty GM, Haugen BR. et al. American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer, revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214
  • 9 Rizzo M, Rossi RT, Bonaffini O. et al. Increased annual frequency of Hashimoto’s thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. Ann Endocrinol (Paris) 2010; 71: 525-534
  • 10 Arena S, Latina A, Baratta R. et al. Chronic lymphocytic thyroiditis: Could it be influenced by a petrochemical complex? Data from a cytological study in South-Eastern Sicily. Eur J Endocrinol 2015; 172: 383-389
  • 11 Bhatia A, Rajwanshi A, Dash RJ. et al. Lymphocytic thyroiditis – is cytological grading significant? A correlation of grades with clinical, biochemical, ultrasonographic and radionuclide parameters. CytoJournal 2007; 30: 41-46
  • 12 Baloch ZW, LiVolsi VA, Asa SL. et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute thyroid fine-needle aspiration state of the Science Conference. Diagnost Cytopathol 2008; 36: 425-437
  • 13 Sahli ZT, Smith PW, Umbricht CB. et al. Preoperative molecular markers in thyroid nodules. Front Endocrinol (Lausanne) 2018; 9: 179
  • 14 Roth MY, Witt RL, Steward DL. Molecular testing for thyroid nodules: Review and current state. Cancer 2018; 124: 888-898